Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 26 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 539524 | NSE: LALPATHLAB

Dr Lal Pathlabs Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 24, 2024, 8:47 pm

Market Cap 24,537 Cr.
Current Price 2,924
High / Low 3,654/1,943
Stock P/E61.1
Book Value 240
Dividend Yield0.82 %
ROCE25.2 %
ROE20.4 %
Face Value 10.0
PEG Ratio6.37

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Dr Lal Pathlabs Ltd

Competitors of

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
NG Industries Ltd 64.0 Cr. 191 230/13611.0 1241.83 %6.50 %5.63 % 10.0
Global Longlife Hospital and Research Ltd 32.0 Cr. 30.5 61.7/27.0 25.90.00 %2.51 %4.72 % 10.0
Gian Lifecare Ltd 19.9 Cr. 19.2 29.0/17.04.84 19.20.00 %29.2 %24.6 % 10.0
Fortis Malar Hospitals Ltd 114 Cr. 61.0 108/44.0 15.969.6 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 36.7 Cr. 6.79 10.3/6.230.87 2.670.00 %15.4 %24.1 % 10.0
Industry Average25,137.47 Cr766.5552.9389.623.09%12.34%12.42%9.12

All Competitor Stocks of

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales431607498497486503534489491541601539545
Expenses309418357388364385390376375395424398401
Operating Profit122189142109121118144113116146178141145
OPM %28%31%28%22%25%23%27%23%24%27%30%26%27%
Other Income141414121289101414181818
Interest455912811998877
Depreciation20192031383639383835363637
Profit before tax1111791318284811037683118152116120
Tax %23%25%26%29%26%28%30%30%32%29%27%29%28%
Net Profit8513496586258725457841118286
EPS in Rs10.0115.7411.406.887.356.928.606.336.809.9013.099.7410.12

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales4525586607919121,0571,2031,3301,5812,0872,0172,227
Expenses3544195045826757939109871,1451,5261,5271,617
Operating Profit98139156210238264294344436561490609
OPM %22%25%24%26%26%25%24%26%28%27%24%27%
Other Income3812202731465551524269
Interest00001111516303829
Depreciation202728282833387377108150144
Profit before tax80119140201237261301310394475344505
Tax %31%33%31%34%34%34%33%27%25%26%30%28%
Net Profit558096133156172200228296350241362
EPS in Rs1,643.22148.2717.5115.9918.6120.4923.9027.1134.9941.3728.6542.85
Dividend Payout %9%7%9%15%16%22%25%44%57%29%21%42%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)45.45%20.00%38.54%17.29%10.26%16.28%14.00%29.82%18.24%-31.14%50.21%
Change in YoY Net Profit Growth (%)0.00%-25.45%18.54%-21.25%-7.04%6.02%-2.28%15.82%-11.58%-49.39%81.35%

Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:15%
5 Years:13%
3 Years:12%
TTM:11%
Compounded Profit Growth
10 Years:16%
5 Years:12%
3 Years:7%
TTM:33%
Stock Price CAGR
10 Years:%
5 Years:14%
3 Years:-6%
1 Year:14%
Return on Equity
10 Years:23%
5 Years:21%
3 Years:20%
Last Year:20%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:43 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital3545583838383838383838384
Reserves1571512604255127058629491,1621,4181,5831,7661,918
Borrowings22827-0-0-0-0-0150533420247198
Other Liabilities10611913411895128145341265309297357397
Total Liabilities2693524756256909161,0911,3741,6612,3432,3832,4542,598
Fixed Assets1271401501661522082094134471,3691,3051,2281,189
CWIP101418103111015561
Investments55938641061451851645965150114289
Other Assets872032863914145546947861,1448939231,1071,119
Total Assets2693524756256909161,0911,3741,6612,3432,3832,4542,598

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +8898122159171197219284398447456535
Cash from Investing Activity +-64-89-113-163-137-172-100-26-212-449-287-24
Cash from Financing Activity +-15-10-10-3213-55-190-139136-283-414
Net Cash Flow9-28-5237646748134-11497

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow96.00111.00129.00210.00238.00264.00294.00344.00286.0028.0070.00362.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days161617171714161415151313
Inventory Days37313344407039382830
Days Payable908997106111144132107127151
Cash Conversion Cycle1616-35-42-47-47-55-60-78-54-87-108
Working Capital Days-39-26-92719170-19-17-14-19-23
ROCE %58%60%48%47%43%38%35%32%33%29%18%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters55.23%55.23%55.23%55.05%55.04%55.04%55.03%55.01%54.61%54.60%54.60%54.60%
FIIs26.82%25.45%23.44%22.37%23.26%25.80%24.89%23.27%24.35%25.36%26.15%25.43%
DIIs5.73%6.57%6.83%6.52%6.27%6.20%6.56%8.34%8.85%9.27%9.40%12.42%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.29%0.29%0.29%0.29%0.29%
Public11.42%12.01%13.80%15.46%14.84%12.38%13.01%12.65%11.48%10.12%9.24%6.95%
Others0.80%0.74%0.70%0.60%0.58%0.56%0.51%0.44%0.41%0.37%0.32%0.30%
No. of Shareholders1,25,9531,35,0681,71,8461,84,5081,71,6021,79,6361,80,1631,74,4441,60,6791,49,9011,46,7411,31,189

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Flexi Cap Fund1,517,7231.68401.87193,8002024-12-24683.14%
HDFC Flexi Cap Fund - Regular Plan1,192,2100.58315.68193,8002024-12-24515.18%
SBI Large & Midcap Fund650,0000.73172.11193,8002024-12-24235.4%
HDFC ELSS Tax Saver Fund539,8000.97142.93193,8002024-12-24178.53%
UTI Mid Cap Fund529,7301.31140.26193,8002024-12-24173.34%
Nippon India Pharma Fund425,0001.57112.53193,8002024-12-24119.3%
PGIM India Midcap Opportunities Fund388,8081.02102.95193,8002024-12-24100.62%
HDFC Hybrid Equity Fund - Regular Plan242,9570.2864.33193,8002024-12-2425.36%
Edelweiss Arbitrage Fund193,8000.4451.32193,8002024-12-240%
UTI Small Cap Fund158,4651.1141.96193,8002024-12-24-18.23%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)43.0528.8241.7035.3327.42
Diluted EPS (Rs.)42.9828.7441.7035.2527.37
Cash EPS (Rs.)60.6046.9355.0044.8336.04
Book Value[Excl.RevalReserv]/Share (Rs.)225.85203.86185.20153.10126.48
Book Value[Incl.RevalReserv]/Share (Rs.)225.85203.86185.20153.10126.48
Revenue From Operations / Share (Rs.)266.73241.93250.45189.72159.63
PBDIT / Share (Rs.)81.2763.7673.5858.5147.83
PBIT / Share (Rs.)64.0645.7460.6149.2439.09
PBT / Share (Rs.)60.5541.2456.9947.3237.25
Net Profit / Share (Rs.)43.4028.9242.0335.5727.31
NP After MI And SOA / Share (Rs.)42.8528.6541.3734.9927.10
PBDIT Margin (%)30.4626.3529.3730.8329.96
PBIT Margin (%)24.0118.9024.2025.9524.48
PBT Margin (%)22.7017.0422.7524.9423.33
Net Profit Margin (%)16.2711.9516.7818.7417.10
NP After MI And SOA Margin (%)16.0611.8416.5118.4416.97
Return on Networth / Equity (%)19.3414.3322.8623.4221.86
Return on Capital Employeed (%)26.8619.9027.2529.5828.40
Return On Assets (%)14.5610.0114.6517.5516.43
Long Term Debt / Equity (X)0.000.050.110.000.00
Total Debt / Equity (X)0.040.140.220.000.00
Asset Turnover Ratio (%)0.910.850.961.011.06
Current Ratio (X)2.422.071.754.183.93
Quick Ratio (X)2.342.001.654.023.68
Dividend Payout Ratio (NP) (%)55.7641.6233.5533.9856.52
Dividend Payout Ratio (CP) (%)39.7825.5525.5426.8742.75
Earning Retention Ratio (%)44.2458.3866.4566.0243.48
Cash Earning Retention Ratio (%)60.2274.4574.4673.1357.25
Interest Coverage Ratio (X)23.1114.1620.3230.4726.05
Interest Coverage Ratio (Post Tax) (X)13.347.4212.6119.5315.88
Enterprise Value (Cr.)18177.2514843.3421493.2321670.2911132.07
EV / Net Operating Revenue (X)8.167.3610.3013.708.37
EV / EBITDA (X)26.7927.9235.0544.4427.93
MarketCap / Net Operating Revenue (X)8.487.5610.4114.278.78
Retention Ratios (%)44.2358.3766.4466.0143.47
Price / BV (X)10.219.1514.4118.1211.31
Price / Net Operating Revenue (X)8.487.5610.4114.278.78
EarningsYield0.010.010.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dr Lal Pathlabs Ltd as of December 26, 2024 is: 3,015.99

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 26, 2024, Dr Lal Pathlabs Ltd is Undervalued by 3.15% compared to the current share price 2,924.00

Intrinsic Value of Dr Lal Pathlabs Ltd as of December 26, 2024 is: 3,305.17

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 26, 2024, Dr Lal Pathlabs Ltd is Undervalued by 13.04% compared to the current share price 2,924.00

Last 5 Year EPS CAGR: 9.59%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 38.83%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -8.58, which is a positive sign.
  3. The stock has a low average Cash Conversion Cycle of -48.42, which is a positive sign.
  4. The company has higher reserves (912.92 cr) compared to borrowings (123.46 cr), indicating strong financial stability.
  5. The company has shown consistent growth in sales (281.92 cr) and profit (280.58 cr) over the years.

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lal Pathlabs Ltd:
      1. Net Profit Margin: 16.27%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: 26.86% (Industry Average ROCE: 12.34%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 19.34% (Industry Average ROE: 11.92%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): 13.34
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 2.34
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 61.1 (Industry average Stock P/E: 42.34)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 0.04
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Dr. Lal Pathlabs Ltd. is a Public Limited Listed company incorporated on 14/02/1995 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1995PLC065388 and registration number is 065388. Currently Company is involved in the business activities of Other human health activities. Company’s Total Operating Revenue is Rs. 1872.71 Cr. and Equity Capital is Rs. 83.35 Cr. for the Year ended 31/03/2022.
    INDUSTRYADDRESSCONTACT
    Hospitals & Medical ServicesBlock E, New Delhi Delhi 110085cs@lalpathlabs.com
    https://www.lalpathlabs.com
    Management
    NamePosition Held
    Brig.(Hony) Dr. Arvind LalExecutive Chairman
    Dr. Om Prakash ManchandaManaging Director
    Dr. Vandana LalWhole Time Director
    Mr. Rahul SharmaNon Executive Director
    Dr. Archana Lal ErdmannNon Executive Director
    Mr. Gurinder Singh KalraIndependent Director
    Mr. Rajit MehtaIndependent Director
    Mrs. Somya SatsangiIndependent Director
    Mr. Rohit BhasinIndependent Director
    Mr. Arun DuggalIndependent Director

    FAQ

    What is the latest intrinsic value of Dr Lal Pathlabs Ltd?

    The latest intrinsic value of Dr Lal Pathlabs Ltd as on 26 December 2024 is ₹3015.99, which is 3.15% higher than the current market price of ₹2,924.00. The stock has a market capitalization of 24,537 Cr. and recorded a high/low of 3,654/1,943 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,918 Cr and total liabilities of ₹2,598 Cr.

    What is the Market Cap of Dr Lal Pathlabs Ltd?

    The Market Cap of Dr Lal Pathlabs Ltd is 24,537 Cr..

    What is the current Stock Price of Dr Lal Pathlabs Ltd as on 26 December 2024?

    The current stock price of Dr Lal Pathlabs Ltd as on 26 December 2024 is 2,924.

    What is the High / Low of Dr Lal Pathlabs Ltd stocks in FY 2024-2025?

    In FY 2024-2025, the High / Low of Dr Lal Pathlabs Ltd stocks is 3,654/1,943.

    What is the Stock P/E of Dr Lal Pathlabs Ltd?

    The Stock P/E of Dr Lal Pathlabs Ltd is 61.1.

    What is the Book Value of Dr Lal Pathlabs Ltd?

    The Book Value of Dr Lal Pathlabs Ltd is 240.

    What is the Dividend Yield of Dr Lal Pathlabs Ltd?

    The Dividend Yield of Dr Lal Pathlabs Ltd is 0.82 %.

    What is the ROCE of Dr Lal Pathlabs Ltd?

    The ROCE of Dr Lal Pathlabs Ltd is 25.2 %.

    What is the ROE of Dr Lal Pathlabs Ltd?

    The ROE of Dr Lal Pathlabs Ltd is 20.4 %.

    What is the Face Value of Dr Lal Pathlabs Ltd?

    The Face Value of Dr Lal Pathlabs Ltd is 10.0.

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lal Pathlabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE